MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tauopathies"

  • 2025 International Congress

    Disease Characteristics of the First 100 Participants in the CurePSP Genetics Program Cohort

    C. Obasi, V. Zhao, C. Martinez, S. Scholz, H. Morris, N. Mcfarland, M. Nance, J. Wang, N. Mencacci, B. Cuoto, T. Foroud, J. Verbrugge, A. Miller, L. Heathers, L. Honig, A. Lang, F. Rodriguez-Porcel, P. Moretti, M. Mesaros, J. Brummet, K. Diaz, A. Wills (Boston, USA)

    Objective: To increase our understanding of the pathogenesis of atypical parkinsonian disorders though genetics, and to build a cohort of individuals for future research. Background:…
  • 2025 International Congress

    Plasma tau-species-containing neuron-derived extracellular vesicles as potential biomarkers for progressive supranuclear palsy

    YC. Zheng, HH. Cai, WY. Kou, ZW. Yu, T. Feng (Beijing, China)

    Objective: This study aimed to develop and validate novel plasma PSP biomarkers based on tau-species-containing neuron-derived extracellular vesicles (NDEVs) in two independent cohorts (discovery and…
  • 2025 International Congress

    4R-TAU seed amplification assay discriminates tauopathies from non-tauopathies and CBD from PSP in post-mortem brain samples

    L. de Mena, M. Fernandez, J. Perez, C. Painous, A. Camara, A. Perez-Soriano, L. Molina-Porcel, E. Artikis, B. Caughey, Y. Compta (Barcelona, Spain)

    Objective: To investigate whether 4R-TAU seed amplification assay discriminates tauopathies from non-tauopathies as well as CBD from PSP in post-mortem brain samples. Background: 4 repeat…
  • 2025 International Congress

    Neuroinflammatory response is determined by HLA genotype in progressive supranuclear palsy

    G. Kovacs, H. Chasiotis, S. Zaheer, J. Wang, J. Li, MC. Tartaglia, S. Fox, A. Lang, S. Forrest (Toronto, Canada)

    Objective: Our aim was to examine whether the HLA haplotypes influence the neuroinflammatory response in a cohort of neuropathologically diagnosed PSP cases. Background: Progressive supranuclear…
  • 2025 International Congress

    The heterogenous compatibility of FDG-PET patterns and tau deposition in vivo in patients with Corticobasal Syndrome

    X. Li, JY. Lu, FT. Liu, J. Wang (Shanghai, China)

    Objective: In this study, we aimed to compare the patterns of 18Fluorodeoxyglucose PET (FDG-PET) with 18F-Florzolotau PET in patients with Corticobasal Syndrome (CBS), and investigate…
  • 2025 International Congress

    Dopa-Responsive Parkinsonism Secondary to Tauopathy: Clinical, Pathological, and Genetic Study

    S. Giri Ravindran, B. Daud Shah, E. Noyes, V. Zherebitskiy, A. Rajput, M. Farrer, A. Rajput (Saskatoon, Canada)

    Objective: To report on the clinical, pathological, and genetic findings of four cases of levodopa-responsive parkinsonism with long survival and tauopathy. Background: The most common…
  • 2025 International Congress

    Unraveling the Genetic Architecture of Progressive Supranuclear Palsy in East Asians

    P. Chen, R. Lin, N. Lee, J. Hsu, C. Tai, R. Wu, H. Chiang, Y. Wu, C. Lu, H. Chang, T. Lee, Y. Chang, C. Lin (Taipei, Taiwan)

    Objective: We aim to elucidate the genetic architecture of progressive supranuclear palsy (PSP) in East Asians through whole-exome sequencing in a multi-center study in Taiwan.…
  • 2025 International Congress

    Utilizing the 15-item modification of the PSPRS rating scale (mPSPRS-15) as the primary endpoint for future clinical trials in progressive supranuclear palsy

    F. Nery, T. Nevmyrych, J. Murphy, S. Wu, Y. Zabar, A. Gafson, S. Bullain, J. O’Gorman (Cambridge, USA)

    Objective: To compare the properties of PSPRS-28, mPSPRS-15, and the rPSPRS-10 and assess their utility as a primary endpoint in PSP trials. Background: Progressive supranuclear…
  • 2025 International Congress

    Elucidating Tau and Alpha-synuclein Co-pathology in RAB39b X-linked Parkinson’s Disease.

    M. Kim, A. Park, E. Chiu, J. Weiss, S. Yu, D. Yearout, C. Zabetian, O. Betancour, M. Davis (Seattle, USA)

    Objective: Elucidate the mechanisms underlying pathogenesis of X-linked Parkinson’s disease (PD) due to the RAB39B p.G192R mutation. Background: RAB39B p.G192R causes X-linked PD with decreased…
  • 2024 International Congress

    Cytokine Profiles as Biomarkers for Neurodegenerative Diseases: An inflammatory study on Parkinson’s Disease and Tauopathies

    A. Jäck, W. Wilfert, C. Palleis, A. Bernhardt, E. Weidinger, S. Katzdobler, U. Fietzek, D. Teupser, J. Levin (Munich, Germany)

    Objective: To investigate the diagnostic and prognostic value of cytokine profiles in cerebrospinal fluid (CSF) and serum of patients with Parkinson's Disease (PD), Progressive Supranuclear…
  • 1
  • 2
  • 3
  • …
  • 14
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley